Myeloma Trial, Recruiting NCT04300998 Sponsor: Memorial Sloan Kettering Cancer Center Condition: Myeloma
Back to Myeloma

Myeloma Trial, Recruiting

NCT04300998
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who are 60 years of age or older (all groups)
  • People who have a confirmed diagnosis of a relapsed or treatment-resistant blood cancer or plasma cell disorder (such as lymphoma or myeloma) and are receiving a commercially approved CAR T-cell therapy (all groups)
  • People who are able to speak and understand English (groups 1 and 4 only)
  • People who score below 26 out of 30 on a cognitive assessment called the MoCA, as assessed by a geriatrician before CAR T-cell treatment begins (group 4 only)

Who may not be able to join:

  • People who have previously received any CAR T-cell therapy, whether as part of a trial or as a standard treatment (all groups)
  • People with a current diagnosis of a major psychiatric condition such as major depression, bipolar disorder, or schizophrenia, based on medical records or personal report (group 1 only)
  • People with a history of a neurological condition, a neurodegenerative disease, or a serious brain injury involving loss of consciousness lasting more than 60 minutes, based on medical records or personal report (group 1 only)
  • People with a current or past history of substance abuse, based on medical records or personal report (group 1 only)
  • People with a history of disease affecting the central nervous system (the brain and spinal cord) (group 4 only)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 26 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Richard Lin, MD, PhD, Memorial Sloan Kettering Cancer Center

Phone: 646-608-2646

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
4 March 2020
Est. completion
4 March 2027

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Number of participants who complete all required assessment visits prior to disease progression or death

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov